BPC-157 is not FDA-approved and is not commercially available as a licensed pharmaceutical product in most countries
References Brello Health Brello Health Review 2025: GLP-1 Telehealth Weight Loss Program With Semaglutide, Tirzepatide, and Personalized Coaching | Newswire Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction - PMC Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment - PMC Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity - PMC Brello Review: Digital Access to Compounded GLP-1 Medications - Sustainable Food Trade Association FDAs Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Some patients benefit from a maintenance dose lower than their peak therapeutic dose, essentially using GLP-1 as a long-term tool rather than a short-term intervention
Product overview It is positioned as a convenient protein option for adults who want to support daily protein intake alongside meals and training
A bonus is that it slims down my face
[DOI] [PubMed] [Google Scholar] 4.Kang E.A., Han Y.M., An J.M., Park Y.J., Sikiric P., Kim D.H., Kwon K.A., Kim Y.J., Yang D., Tchah H., et al
